Treatment with this combined formulation in mice improved pancreatic ductal adenocarcinoma (PDAC) immunotherapy and reversed tumor immunosuppression of M2-like tumor-associated macrophages by disrupting the galectin-9/dectin-1 axis [99]. Here, CLEC7A is linked to neoplasm.